A2B-356

N/A

Report date: 2025/08/15 10:26:29

Base Information

Drug NameA2B-356

Drug Alias NameA2B-356

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesA2 Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesA2 Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A